SELLAS Life Sciences (SLS) Current Assets (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Current Assets data on file, last reported at $111.2 million in Q1 2026.

• On a quarterly basis, Current Assets rose 247.7% year-over-year to $111.2 million in Q1 2026; TTM through Mar 2026 was $111.2 million, a 247.7% increase from a year earlier, with the FY2025 full-year figure at $75.2 million, up 360.65% from the prior year.
• Current Assets for Q1 2026 stood at $111.2 million, up from $75.2 million in the prior quarter.
• Over the last five years, Current Assets for SLS reached as high as $111.2 million in Q1 2026 and fell as low as $3.2 million in Q4 2023.
• Historically, Current Assets has averaged $29.9 million across 5 years, with a median of $22.6 million in 2022.
• Across the five-year window, Current Assets tumbled 82.14% in 2023 and jumped 414.72% in 2024, its largest moves.
• Year by year, Current Assets stood at $17.8 million in 2022, then plunged by 82.14% to $3.2 million in 2023, then soared by 414.72% to $16.3 million in 2024, then soared by 360.65% to $75.2 million in 2025, then soared by 47.81% to $111.2 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $111.2 million in Q1 2026, $75.2 million in Q4 2025, and $49.1 million in Q3 2025.